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Background: Natalizumab (Tysabri, Biogen Idec and Elan Pharmaceuticals) significantly reduces the relapse rate and
disability progression, and improves health-related quality of life (HRQoL), in patients with relapsing-remitting
multiple sclerosis. We investigated the impact of natalizumab on patient-reported outcomes (PROs) in a real-world
setting.
Methods: PRO data were collected from patients enrolled in a longitudinal real-world study using validated
measures administered as surveys before the patients initiated natalizumab treatment and after the 3rd, 6th, and
12th monthly infusion. HRQoL, ability to carry out daily activities, disability level, and impact on cognitive
functioning and fatigue were assessed.
Results: A total of 333 patients completed 12 months of assessments. After 12 months of natalizumab treatment,
69% to 88% of patients reported a positive outcome (either an improvement or no further decline) in all PRO
measures assessed. Significant improvements in general and disease-specific HRQoL were observed after three
infusions, both with physical (p < .01) and psychological (p < .001) measures, and were sustained after 12 infusions
(all p < .001). The impact of multiple sclerosis on cognitive functioning and fatigue was significantly reduced (both
p < .001 after 3 and 12 infusions).
Conclusions: PRO measures were improved with natalizumab in a real-world setting. The improvements were
observed as early as after 3 months and sustained over a 12-month period. The improvements in PROs show that,
in clinical practice, the clinical benefits of natalizumab are translated into patient-reported benefits.
Keywords: Cognitive function, Health-related quality of life, Multiple sclerosis, Natalizumab, Patient-reported outcomesBackground
Multiple sclerosis (MS) patients commonly experience a
range of debilitating symptoms [1]. The progressive na-
ture of the disease leads to increasing disability, with
both physical and mental impairment concomitant with
increasing impact on patients’ general quality of life,
family and social life, and employment status [2,3]. MS
patients rank their quality of life to be lower than not
only that of the general population but also lower than
that of patients with other chronic diseases [4-6]. MS,* Correspondence: JStephenson@healthcore.com
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distribution, and reproduction in any mediumwhich affects mainly young adults, imposes a substantial
economic burden on society, reflected both in healthcare
costs and loss of productivity [7]. In general, MS therapy
aims to reduce the rate of disease relapses, delay disease
progression, and manage the symptoms of the disease [1].
Natalizumab (Tysabria, Biogen Idec and Elan Pharma-
ceuticals) is indicated as monotherapy for treatment of
remitting-relapsing MS. In the AFFIRM and SENTINEL
studies, natalizumab was demonstrated to significantly
reduce annualized relapse rate and the risk of sustained
disability and to reduce disease activity over 2 years [8-10].
In addition to clinical measures, improvements in health-
related quality of life (HRQoL), which is a patient-reportedntral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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http://www.hqlo.com/content/10/1/155outcome (PRO), were also reported [11]. A positive impact
of natalizumab on PROs has also been demonstrated in
short-term and small, observational, real-world studies
[12,13].
Given the impact of MS on patient lives, it is import-
ant to complement clinical evidence with PRO evidence,
as it provides insight into patients' condition from their
own perspective [14]. PROs assessed in the context of
real-world observational studies may more accurately re-
flect the effectiveness of a drug in the general patient
population, as perceived by patients themselves, than in
a clinical trial where certain patient groups may have
been excluded.
The study reported here is the first large, real-world, 12-
month longitudinal study assessing MS patients’ experi-
ences with natalizumab in the United States, across a
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*One natalizumab infusion every 4 weeks 
Figure 1 (A) Study design. (B) Disposition of patients during the 12-monMethods
Study design and patients
A 1-year, longitudinal, observational, single-arm study
was designed to assess MS patient experiences before
and after starting treatment with natalizumab at a
monthly dose of 300 mg administered intravenously
(Figure 1A). The study consisted of four 20–25-minute
surveys administered at baseline before initiating natali-
zumab, and three follow-up surveys administered be-
tween the 3rd and 4th, the 6th and 7th, and the 12th
and 13th infusions.
Patients who were newly prescribed natalizumab in
the United States were identified through the manufac-
turer’s restricted drug distribution program, the Tysabri
Outreach Unified Commitment to Health (TOUCHb)
[15], and were contacted between July 2008 and January
2009 by telephone by trained interviewers. The Humanted
urvey
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Review Board approved the protocol, recruitment, con-
sent, and survey procedures. All patient data were
handled in compliance with the regulations of the US
Insurance Portability and Accountability Act of 1996.
Study participation eligibility criteria were the ability
to understand English, age greater than 18 years, the
ability to provide informed verbal consent, and a pre-
scription for natalizumab without the patient having
received the first infusion. Potential participants were
excluded if they had already had the 4th, 7th, or 13th in-
fusion, respectively, at the time of the follow-up surveys,
or if they were no longer receiving natalizumab after the
baseline survey.
PRO measures
Patients completed the following assessments: general and
disease-specific HRQoL, ability to carry out daily activities,
disability level, cognitive functioning, and fatigue status.
The baseline survey also contained questions relating to
patient demographics and clinical characteristics.
General HRQoL (Short-Form 12 Version 2 [SF-12v2])
The SF-12v2 is a generic HRQoL measure that consists
of 12 questions selected from the widely used SF-36
health survey [16]. It was also used in the AFFIRM and
SENTINEL clinical trials [11]. It provides information
on physical and mental health via the Physical and Men-
tal Component Summary (PCS and MCS) scores, which
are calculated as norm-based scores ranging from 0 to
100. Higher scores represent better HRQoL, with the
average US population score being 50 for each [17]. A
score change of 5 points in MCS or PCS scales is con-
sidered to be clinically meaningful [18]. No change or an
improvement of at least 5 points was assumed in this
study to be a positive outcome for the patient.
Disease-specific HRQoL (Multiple Sclerosis Impact Scale
[MSIS]-29)
The MSIS-29 is a disease-specific HRQoL measure. It
assesses the physical (20 questions) and psychological
(9 questions) impact of MS, provided as separate scores on
a scale of 0 to 100, where lower scores represent better
HRQoL [19]. MSIS-29 scores can be categorized so that
0–19 represent “no problems”; 20–39, “few problems”; 40–
59, “moderate problems”; 60–79, “quite a few problems”;
and 80–100, “extreme problems” [20]. No change or an
improvement of at least one score category was assumed
in this study to be a positive outcome for the patient.
Ability to perform daily activities (Functional Status [FS])
The FS scale assesses the ability of MS patients to per-
form their normal daily activities at the present time
using a single question with a 5-point scale ranging fromFS1 to FS5, with FS5 representing the greatest impair-
ment [Additional file 1]. The scale is modified from a
self-assessment questionnaire measuring neurological
impairment [21]. No change or an improvement of at
least one step of the scale was assumed in this study to
be a positive outcome for the patient.
Disability level (Disease Steps [DS])
The DS scale consists of a single item that assesses MS
patients’ level of disability on a 7-point scale ranging
from DS0 to DS6, with DS6 representing the greatest
disability [22] [Additional file 2]. It is validated against
the Expanded Disability Status Scale [23], a widely used
physician-reported measure of disability. No change or
an improvement of least one step on the scale was
assumed in this study to be a positive outcome for the
patient.
Cognitive functioning (Medical Outcomes Scale-Cognitive
Functioning [MOS-Cog])
The MOS-Cog instrument measures the frequency with
which MS has an impact on cognitive function [24]. It
consists of six items, with responses ranging from 1
(“All of the time”) to 6 (“None of the time”). Scores
range from 6 to 36, with higher scores representing less
impact on cognitive functioning. No change or an im-
provement of least one point on the scale was assumed
in this study to be a positive outcome for the patient.
Fatigue status (Modified Fatigue Impact Scale [MFIS]-5)
The MFIS-5 is an abbreviated version of the MFIS-21,
which is a modified form of the Fatigue Impact Scale
[25,26]. The MFIS-5 consists of five questions that assess
the impact of fatigue on physical, cognitive, and psycho-
social functioning, with five response levels ranging from
0 (“Never”) to 4 (“Almost always”). Total scores range
from 0 to 20, with higher scores representing a greater
impact of fatigue. No change or an improvement of least
one point on the scale was assumed in this study to be a
positive outcome for the patient.
Statistical methods and sensitivity analysis
Univariate analyses were performed to describe baseline
demographics and compare PROs at each time point.
Linear mixed effects models were used to evaluate out-
come changes over time, controlling for age, disability
level, functional status, years since diagnosis, number of
comorbidities, and number of MS drugs used prior to
natalizumab. Adjusted mean scores for all outcomes
estimated from the linear mixed effects models are
reported. Statistical Analysis System (SAS) version 9.2
was used for all analyses (SAS Institute Inc., Cary, NC,
USA).
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assess the validity of the results and to ensure that loss
of patients during follow-up did not cause any bias in
the results: (1) the baseline characteristics, patient-
reported level of disability, and years since diagnosis of
patients who completed all three follow-up surveys were
compared with corresponding variables of patients who
completed only the baseline survey; and (2) mixed-
effects models were developed using all patients who
had received at least one natalizumab infusion to test
the robustness of the models.
Results
Patients
A total of 1,275 patients fulfilled the inclusion criteria
and completed the baseline survey. At the end of the 12-
month follow-up, 786 patients had completed at least
one follow-up survey – 333 patients (42%) had com-
pleted all three follow-up surveys and 157 patients had
withdrawn from the study. In total, 559 patients were
excluded as they never started, were no longer taking
natalizumab, or had received too many infusions at the
time of the follow-up surveys. There were 226 patients
who were lost to follow-up and did not complete any
follow-up surveys (Figure 1B).
The study participants’ average age was 47 years
(standard deviation 10 years). The majority were female
and Caucasian, reflecting the MS patient population as a
whole [1]. Almost all patients had been treated with one
or more disease-modifying treatments (DMTs) before
initiating natalizumab. Table 1 summarizes patient
demographics and characteristics at baseline.
There was considerable impact of MS on patients’ lives
at baseline. The majority of patients reported generalTable 1 Patient demographics and characteristics at baseline
Age, years; mean (SD)
Female (%)
Caucasian (%)
Years since MS diagnosis; mean (SD)
Number of MS DMTs used prior to natalizumab; mean (SD)
Proportion of patients treated with 1 DMT prior to natalizumab
Proportion of patients treated with≥ 2 DMTs prior to natalizumab
SF-12v2 PCS; mean (SE)
SF-12v2 MCS; mean (SE)
Proportion of patients with SF-12v2 PCS≤ 50a
Proportion of patients with SF-12v2 MCS≤ 50a
FS; mean (SD)
DS; mean (SD)
aAverage score for the general US population. bFS3: Able to carry out about only ha
a cane/unilateral support for walking greater distances, but can walk at least 25 fee
DMT disease-modifying treatment, DS Disease Steps, FS Functional Status, MCS Men
Summary, SD standard deviation, SE standard error, SF-12v2 Short-Form 12 VersionHRQoL scores below those of the US general popula-
tion. Additionally, 86% reported being at FS2 or above,
meaning that their ability to perform daily activities was
impaired, ranging from mild limitations to requiring as-
sistance with basic self-care. Almost all patients (96%)
also reported being at DS1 or above, meaning that they
experienced some degree of disability.
General and disease-specific HRQoL
Patients reported statistically significant improvements
in physical and mental aspects of their general and
disease-specific HRQoL during the course of the study.
These improvements were observed starting from the
first follow-up survey after three natalizumab infusions
and were sustained throughout the study (Figure 2A,
and 2b). This translated into a positive outcome for a
majority of patients; 79% to 84% of patients reported ei-
ther a meaningful improvement or no change in their
general HRQoL and 85% to 86% of patients reported
improved or stable disease-specific HRQoL after 12 infu-
sions (Figure 2C).
Ability to perform daily activities and disability level
After three natalizumab infusions, 88% and 87% of patients
reported a positive outcome in their ability to perform
daily activities and their disability level compared with
baseline, respectively, seen as either a meaningful improve-
ment or no change in FS or DS score. The effect was sus-
tained to after 12 natalizumab infusions (Figure 3).
Cognitive functioning and fatigue
After three natalizumab infusions, patients reported a
statistically significant reduction in the impact of MS on
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Figure 2 Changes in general and disease-specific HRQoL over
12 natalizumab infusions. (A) Mean SF-12v2 scores (± SE). (B)
MSIS-29 scores (± SE) at baseline prior to natalizumab initiation and after
the 3rd and 12th infusion. Because of missing data for covariates in their
respective models, n values for SF-12v2 were 317 for PCS and 320 for
MCS, and 328 for MSIS-29. p values were from analyses of variance
performed on the adjusted means estimated by the mixed-effect model
controlling for infusion, age, baseline DS, baseline FS, and also for years
since diagnosis for the PCS/physical analyses. (C) Proportion of patients
with improved, stable, or worsened HRQoL. The scores had to change by
at least 5 points for SF-12v2, or by 19 points (one score interpretation
category for MSIS-29) for the patient’s HRQoL to be considered improved
or worsened. *p < .0001; †p< .01. HRQoL health-related quality of life; MCS
Mental Component Summary; MSIS-29 Multiple Sclerosis Impact Scale 29;
PCS Physical Component Summary; SE standard error; SF-12v2 Short-
Form 12 Version 2.
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creased MFIS-5 scores (Figure 4A, 4B). The improvement
in cognitive functioning with natalizumab was sustained
to after 12 infusions. Compared with baseline, 65% to 69%
of patients experienced either a meaningful improvement
or no change in the impact of MS on cognition and fa-
tigue after 12 natalizumab infusions (Figure 4C).
Sensitivity analysis
A comparison of the baseline demographics and charac-
teristics (age, years since MS diagnosis, number of MSdrugs prior to natalizumab, number of comorbidities,
DS and FS level, proportion of females, proportion of
Caucasians, education level, employment status, and in-
come) of the 1,275 patients who completed the baseline
survey did not show any significant difference from
those of the 333 patients who completed the 12-month
survey. A further sensitivity analysis was performed
using a mixed effects model with all available patient
data at each time point and the same covariates as the
linear mixed-effect models, using patient data included
in the final analysis. The resulting SF-12v2 (MCS and
PCS), MSIS-29 (psychological and physical impact),
MOS-Cog, and MFIS-5 scores for the 3- and 12-month
time points using this analysis were significantly diffe-
rent from baseline (all p < .0001), which was consistent
with the results of the 333 patients who completed the
12-month survey (with the exception of SF-12-v2 PCS;
p = .056 at 3 months compared with baseline).Discussion
PROs range from subjective measures, such as perceived
quality of life or the ability to perform daily activities, to
more objective and symptomatic measures, such as
levels of physical disability. Some of these aspects are
difficult to measure clinically, but nonetheless contribute
considerably to the experience of MS. The effectiveness
of a therapy in patients’ lives as a whole can therefore be
assessed using PRO measures in addition to clinical data.
Another factor impacting the effectiveness of a therapy
that is difficult to address in a clinical trial is the hetero-
geneity of a general patient population, since certain
patients groups (for example, those with comorbidities)
that may confound the results in the trial are excluded.
Real-world observational studies, therefore, complement
evidence from clinical trials, and evidence of real-world
effectiveness is becoming increasingly important in
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Figure 3 Changes in ability to carry out daily activities and disability level over 12 natalizumab infusions. Proportion of patients with
improved, no change or worsened ability to carry out daily activities (FS) or disability level (DS) after the 3rd and 12th natalizumab infusion are
shown. Score changes corresponding to at least one step in the FS or DS scales were required for the patient’s ability to carry out daily activities
or disability level to be considered improved or worsened. DS Disease Steps; FS Functional Status.
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sical symptoms [1], which, despite being difficult to
measure clinically, can be perceived as debilitating by
patients. PROs can be used to assess the impact of these
symptoms on patients’ lives. Natalizumab is an effective
treatment that has been shown to reduce relapses and
delay disability progression [8]. This longitudinal study
provides evidence that further supports the effectiveness
of natalizumab and suggests a positive effect on PRO
measures, which were observed from 3 months after
treatment initiation and sustained over the 12-month
study period.
At the start of the study, most patients reported that
MS had a considerable negative impact on their lives,
affecting both physical and psychological aspects, despite
already having received an average of two DMTs. The
patients’ general HRQoL scores were below the scores of
the average US population, and the majority had pro-
blems with mobility and the ability to carry out daily ac-
tivities. This poor health status is typical for MS
patients, who consistently have a lower HRQoL than
both the population without MS [3,27,28] and patients
with other chronic diseases, such as diabetes, heart di-
sease, stroke, and arthritis [29]. Fatigue is also a com-
mon problem for MS patients; in fact, the majority
describe fatigue as the worst or one of the worst symp-
toms [25]. Fatigue can also exacerbate other symptoms,
such as balance, vision, and cognitive problems [29,30].
Because MS is a progressive disease, the absence of a
worsening of symptoms is a positive outcome. Follo-wing initiation on natalizumab, 65% to 88% of patients
reported scores indicating a positive outcome in all PRO
measures assessed. What is more, not only was there no
further deterioration of the PRO measures assessed, but
symptoms were actually improved in a substantial pro-
portion of the patients. Approximately half of patients
reporting a positive outcome in their general and
disease-specific HRQoL assessments had meaningful
improvements in their scores after 12 months compared
with baseline. This is consistent with improvements in
HRQoL reported by natalizumab-treated patients in ran-
domized clinical trials [11] and in a 3-month real-world
study [12]. Similarly, more than a quarter of patients
reported improvements in their disability level, their
ability to carry out daily activities, and the impact of MS
on fatigue and cognition. Improvements such as these
have previously been reported in small European studies,
in which natalizumab was associated with decreased fa-
tigue [13], a reduction in cognitive impairment [31], and
improvements in mobility and reduced disease activity
in patients previously treated with interferon beta or gla-
tiramer acetate [32].
Improvements in all PRO measures investigated were
already observed after three natalizumab infusions and
were sustained over the 12-month study period. This
indicates that the impact of natalizumab occurs rapidly.
Post hoc analyses from the AFFIRM and SENTINEL
clinical trials demonstrated that within the first 3
months of natalizumab treatment, a significant reduction
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Figure 4 Changes in the impact of MS on cognitive functioning
and fatigue over 12 natalizumab infusions. (A) Mean MOS-Cog
(± SE) and (B) MFIS-5 scores (± SE) at baseline prior to natalizumab
initiation and after the 3rd and 12th infusion. Because of missing
data for covariates in their respective models, n values for MOS-Cog
were 331 and 333 for MFIS-5. p values were from analyses of
variance performed on the adjusted means estimated by the mixed
effect model controlling for infusion, age, baseline DS, baseline FS,
years since diagnosis, and infusion, age, baseline DS, baseline FS,
number of comorbidities for MOS-Cog, and number of MS drugs
taken prior to natalizumab for MFIS-5. (C) Proportion of patients with
improved, stable, or worsened cognitive functioning (MOS-Cog) and
fatigue (MFIS-5). MFIS-5 and MOS-Cog scores had to change by at
least one score point to be considered changed. *p < .0001. DS
Disease Steps; FS Functional Status; MFIS Modified Fatigue Impact
Scale - 5 items; MOS-Cog Medical Outcomes Scale-Cognitive
Functioning; SE standard error.
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This rapid effect of natalizumab on the annualized re-
lapse rate has also been observed in the TOP study, a
clinical practice–based observational study [33].
There are no universally acknowledged minimal score
changes that correspond to clinically meaningful
changes in patients for any of the PRO measures used in
this study, with the exception of SF-12v2 (which, as itis normalized, is directly comparable to the scoring of
SF-36, for which a score change of at least 5 constitutes
a clinically meaningful change [18]). However, the steps
in the FS and DS scales correspond to clearly defined
levels of ability or disability (see Additional files 1 and 2)
and a change of one step is therefore a clearly noticeable
difference to the patient. Similarly, a MSIS-29 score
change of at least one category, as defined by the creator
of the measure, which corresponds to different degrees
of problems caused by MS, would presumably be a
meaningful difference for the patient. For both MOS-
Cog and MFIS, a 1-point score corresponds to a defined
category of how often MS impacts aspects of cognition
and fatigue. It is therefore reasonable to assume that the
score changes reported are meaningful to the patient.
This was an observational, single-arm prospective
study and, as such, has recognized limitations. Since the
data presented are longitudinal comparisons within the
same population, it is uncertain whether the reported
improvements in PROs are a direct result of treatment
with natalizumab. However, evidence from randomized
clinical trials has shown that, in contrast to natalizumab-
treated patients, the HRQoL of MS patients receiving
placebo worsens over time [11]. Some of the PRO data
could also be affected by recall bias, as the patients were
asked to consider a period of up to 4 weeks in the past.
In addition, results could be affected by selection bias, as
the full set of 12-month data was only available for 333
of the 1,275 patients who were enrolled in the study.
However, most of the patients were excluded from ana-
lysis because they did not meet study eligibility criteria.
In addition, a sensitivity analysis comparing the demo-
graphics and characteristics of the patients completing
the 12-month survey found that they were not signifi-
cantly different from those of the patient group complet-
ing the baseline survey. Furthermore, a sensitivity
analysis that included data for all available time points
from all patients who received at least one natalizu-
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over time. The self-reported MOS-Cog instrument used
to determine cognitive impairment does not provide an
objective measure of cognitive functioning similar to
that obtained through neuropsychological testing. How-
ever, our intent in using the instrument was not to pro-
vide a quantitative measure of cognitive functioning but
to determine how day-to-day cognitive impairment was
perceived by patients and how those perceptions chan-
ged over time. In this regard, the MOS-Cog is a reliable
scale [24]. Although it is preferable to use the long form
of the MFIS in evaluating the impact of fatigue, the
abbreviated version, the MFIS-5, was developed for
occasions when time is limited, such as in the survey
reported here [26]. The MFIS-5 consists of the five items
most strongly correlated with the total MFIS score, and
the items assess the impact of fatigue in terms of phys-
ical, cognitive, and psychosocial functioning. The use of
the abbreviated scale thus provided a reliable snapshot
of the effects of fatigue given the limited time available.
Conclusions
Overall, this longitudinal, real-world study demonstrates
that natalizumab leads to improvements in PROs from as
early as after 3 months of treatment, and that these posi-
tive effects are sustained for 12 months. The improve-
ments in PRO measures show that the reported clinical
effects of natalizumab are translated into tangible benefits
for patients, improving their mental and physical health
and positively impacting many aspects of their daily lives.
Endnotes
aTysabri is a registered trademark of Elan Pharmaceuti-
cals Inc, San Francisco, CA, USA.
bTOUCH is a registered trademark of Elan Pharmaceuti-
cals Inc, San Francisco, CA, USA.
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